Randomized Treatment of Brain Metastasis with Gamma Knife Radiosurgery, Whole Brain Radiotherapy or Both

Joel W. Goldwein, MD
OncoLink co-Editor-In-Chief
Last Modified: October 23, 2000

Presenter: P. B. Chougule
Affiliation Rhode Island Hospital/Brown University, Providence, RI


Brain metastases develop in approximately 25% of all cancer patients. Management with whole brain RT may palliated these patients, but survival remains dismal. This report is of a group of patients randomized to either whole brain RT (WBRT), Gamma Knife Therapy (GK) or both (WBRT+GK).


  • Patients were randomized to WBRT, GK or WBRT+GK, stratified by treatment site

  • Outcomes were compared for survival and local control


  • Patients were evenly distributed to the 3 arms; 34 for WBRT, 35 for GK+WBRT and 36 for GK

  • Median survival was between 5 - 7 months, and was not different for any group

  • Local control was 52% for the WBRT group, 82% for the WBRT+GK group, and 79% for the GK group (p = .0003)

  • The risk of developing a new brain lesion in un-irradiated brain was significantly higher (approx 40%) in patients who received GK therapy vs approx 20% in patients treated with WBRT or WBRT + GK

  • Surgically resected patients had a better outcome, seen primarily in patients who did not receive GK

Author's Conclusions:

  • GK therapy does not impact on survival

  • GK therapy results in improved local control

  • The risk of developing new brain lesions in patients who do not receive WBRT is higher than those who do

  • GK therapy in conjunction with whole brain RT may improve local control for some patients with brain matastases but probably does not impact survival.

Clinical/Scientific Implications:

  • Selection of patients who underwent surgical resection may have had an impact on the outcome of this study


Eight Tips for Addressing Medical Billing Issues
by Christina Bach, MSW, LCSW, OSW-C
May 25, 2016